University of Connecticut

OpenCommons@UConn
SoDM Masters Theses

School of Dental Medicine

June 1991

Antigen Specific Induction of T Cell Derived
Antigen Binding Molecules
Marianne Murray Urbanski

Follow this and additional works at: https://opencommons.uconn.edu/sodm_masters
Recommended Citation
Urbanski, Marianne Murray, "Antigen Specific Induction of T Cell Derived Antigen Binding Molecules" (1991). SoDM Masters Theses.
143.
https://opencommons.uconn.edu/sodm_masters/143

ANTIGEN SPECIFIC INDUCTION OF
T CELL DERIVED ANTIGEN BINDING MOLECULES

Marianne Murray Urbanski
B.A., College of the Holy Cross, 1982
D.M.D., The University of Connecticut, 1986

A Thesis
Submited in Partial Fulfillment of the
Requirements for the Degree of
Master of Dental Science
at
The University of Connecticut
1991

APPROVAL PAGE
Master of Dental Science Thesis

ANTIGEN SPECIFIC INDUCTION OF
T CELL DERIVED ANTIGEN BINDING MOLECULES

Presented by
Marianne M. Urbanski, B.A., D.M.D.

---I~~~.:...........;;~~---6:;...........a.<-----.;;;.4~2L&.~~

Major Adviser

Robert
Associate Adviser

E. Cone

(/~/~~~
~k~-

_ _ _~ _...............

......iilIIIo..

_

Clarence L. Trummel

Associate Adviser

External Reader ----~~~~-~--------

The University of Connecticut

1991
ii

ACKOWLEDGEMENTS

There are few times in a person's life when she has the opportunity to
work with such a wonderful man as Dr. Bob Cone. He not only demonstrated
extraordinary patience with me during my research training but he also
provided me with a wealth of knowledge and emotional support. I thoroughly
enjoyed working in his lab and I will forever remember that he introduced me to
research in immunology.
I would also like to thank Dr. Clarence Trummel who was an Associate
Advisor for my masters committee and the Chairman of Periodontology.

He

continually demonstrated understanding and lended support to his residents. I
am also grateful to Dr. Chi-Kuang Huang, who served on my thesis committee
and provided me with helpful hints during my research endeavors.
I would also like to thank Dr. Frank Nichols, who served as my Program
Director.

He has been my teacher for many years and was extremely

instrumental in my career development. In addition, I would like to thank the
other members of the Department of Periodontology, Dr. John Nalbandian, Dr.
Paulette Tempro, Dr. Robert Davidson, and Dr. Michael Brown, for making my
graduate experience so rewarding.
This project would never have been possible if I hadn't had the excellent
technical training of James Kristie.

His helpful hints in organization and

laboratory techniques will always be remembered. Together with Dr. Marianne
DiBrino and Dr. John Fitzgerald, James provided me with an exceptionally
friendly, intellectually stimulating, and enjoyable work environment.

iii

I would also like to thank my husband, Joe, for his continued support for
my career. He has stood beside me for many years, and without his unending
patience and love this project would not have been possible.

Finally I would

like to thank God for giving me my wonderful daughter, Laura. It is for her that I
dedicate this work.

iv

TABLE OF CONTENTS
PAGE

1

INTRODUCTION
OBJECTIVE

3

SPECIFIC OBJECTIVES

3

4

LITERATURE REVIEW
GENERAL

4

FUNCTIONS OF SOLUBLE TABM

6

A) Immunoregulation

6

B) TABM in Immune Responses

10

TABM AND THE T CELL RECEPTOR

11

15

MATERIALS AND METHODS
ANIMALS

15

ANTI-TABM

15

IMMUNIZATION

16

THYMOCYTE PREPARATION

16

ELISA

17

PURIFICATION OF TABM BY AFFINITY

18

FOR ANTIGEN
IMMUNOBLOT ANALYSIS

18

DATA ANALYSIS

19

v

PAGE
RESULTS

20

DETECTION OF TABM IN THE HUMORAL
IMMUNE RESPONSE
STORAGE OF SERA FOR TABM

20
21

DOSE RESPONSE OF TABM AND IMMUNOGLOBULIN
PRODUCTION

22

ANTIGEN SPECIFICITY OF TABM PRODUCTION

22

DETERMINATION THAT TABM ARE T CELL DERIVED

23

TABLES AND FIGURES

25

DISCUSSION

43

CONCLUSIONS

48

REFERENCES

49

vi

LIST OF TABLES

.E..ag.e.

Table
1.

Sample Calulation for TABM Production

vii

25

LIST OF FIGURES

~

Figure
1A.

TABM Production in the Primary Response

26

1B.

Immunoglobulin Production in the Primary Response

27

2A.

TABM Production in the Secondary Response

28

2B.

Immunoglobulin Production in the Secondary Response

29

3A.

Primary Response: TABM and Immunoglobulin

30

3B.

Secondary Response: TABM and Immunoglobulin

31

Storage of Sera for TABM

32

5A.

Dose Response of TABM Production

33

5B.

Dose Response of Immunoglobulin Production

34

5C.

Dose Response of TABM and Immunoglobulin

4.

Production

35

6A.

Antigen Specificity of TABM: Immunized with BSA

36

68.

Antigen Specificity of TABM: Immunized with LYS

37

7A.

Immunoblot of TABM Specific for BSA

38

7B.

Immunoblot of Immunoglobulin Specific for BSA

39

8A.

Production of TABM in Unreconstituted scid mice

40

8B.

Production of TABM in Reconstituted scid mice

41

8C.

Production of Immunoglobulin in Reconstituted scid mice 42

viii

INTRODUCTION

Upon interaction with antigen, T and B lymphocytes respond to the
stimulus in a highly specific manner. Antigen stimulated B cells proliferate
and differentiate into immunoglobulin secreting cells which secrete
immunoglobulin specific for the inducing antigen. The antigen combining site
of the secreted products is identical to the antigen combining site of the B cell
membrane immunoglobulin receptor.
Antigen may also interact with the T cell through the T cell receptor
(TcR), and this response is usually dependant on antigen recognition in
association with Major Histocompatibility Proteins (MHC). Some investigators
have shown, however, that T cells also produce antigen binding molecules
(TABM) which bind nominal antigen and are not restricted by MHC
glycoproteins.

These molecules may be either soluble (sTABM) or

membrane-associated (mTABM).

The soluble form generally function as

effector molecules [1-8] and the membrane form are primarily antigen
receptors [9]. The effector function of the TABM may be either to help or to
suppress the immune response depending on their structure and association
with other proteins [1, 3].

In addition, they may be involved in

immunoregulation and hypersensitivity on a systemic level.
Various studies [10, 11] have shown that injection of supernatants of T
cells ( or a T cell hybridoma) into animals renders them unresponsive to a
specific antigen. The factor responsible for this was later shown to be a T-cell
antigen specific protein (TABM).

Similar experiments have shown TABM
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augment: A) antigen specific antibody responses [12, 13], B) DTH response
[14] and C) specific CTL responses [15]. In addition, these molecules have
been shown to transfer the ability to elicit an immediate hypersensitivity
reaction independent of IgE [16].
Various investigators have identified different TABM based on their
specific antigen binding. TABM have been isolated from: A) culture media of T
cell hybrids [17, 18], B) clones [4, 5, 19] or sensitized T cells [2], C) serum [16,
20] D) ascites fluid of antigen-specific T cell hybrids [21]. These proteins are
different from the B cell produced immunoglobulin and the MHC-restricted T
cell receptor (TCR).

In general, TABM are acidic, hydrophobic and tend to

aggregate. The primary structure of TABM appears to be a 110 kD protein
which reduces to 72 kD, 45 kD and 25 kD subunits. In addition, a 140 kD
form has been isolated which may be a disulfide linked multimer [21].
TABM

require

an

accessory

molecule

to

demonstrate

immunoregulatory activity. These additional factors are not antigen specific;
they determine the genetic restrictions of the TABM-accessory molecule
complex and bear determinants bound by anti-I-J or anti-Ia antibodies [3]
Some evidence has shown that the function of the regulatory factor is
determined by the TABM, while the target cell is determined by the accessory
molecule [22]. These findings represent a new kind of immune response that
involves antigen specific (not MHC associated) T cell produced molecules.
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OBJECTIVE

By definition, TABM are proteins that bind antigen specifically. Many
investigators have isolated these proteins and have demonstrated their potent
immunoregulatory effects. However, no one has demonstrated that formation
of TABM in vivo is inducible by a specific antigen. If these proteins can be
shown to be inducible in animals upon antigenic stimulation, it will indicate
that these cells can be triggered at the site of antigen challenge to execute
their functions. Because we already know of the extensive involvement of
these molecules in immunoregulation, this indicates great biologic
significance. This project attempted to substantiate prior observations that
soluble TABM are antigen specific proteins that are secreted byT cells and are
different from B cell produced immunoglobulin.
The goal of this investigation, therefore, was to demonstrate that the
production of T cell antigen binding molecules (TABM) in mice is inducible
upon stimulation with antigen and to demonstrate that this response is antigen
specific.

SPECIFIC OBJECTIVES

1) To demonstrate that TABM production in vivo is inducible.
2) To demonstrate that these TABM are antigen specific.
3) To show that these TABM are T cell derived.

LITERATURE REVIEW

GENERAL

Some T cells produce soluble molecules which are not restricted by
gene products of the major histocompatibility complex (MHC) in their
recognition of antigen [3, 7, 9, 18, 21]. These antigen binding molecules
(TABM) may have an effector role in immunoregulation [3-5, 8, 22-25] or may
have an affector role in immune responses such as contact sensitivity [1, 2,
16, 26-29]. TABM may also be found associated with the cell membrane
where they may function as antigen receptors [9, 21]. Membrane TABM
(mTABM) have been found on at least 80% of adult murine thymocytes and
they are expressed by day 16 of gestation [30, 31]. In addition, thymic and
peripheral mTABM appear to express similar epitopes suggesti ng
similarities between thymic and peripheral mTABM.
The heterodimeric

aJ3

T cell Receptor (TcR), unlike TABM, does not

possess this ability to bind to nominal antigen with high affinity; its
recognition is dependent on the association of antigen with MHC
glycoproteins. It also differs from these soluble products in molecular size [3,
9, 20]. The basic subunit size of TABM is a Mr 22,500 polypeptide which
may form multimers of Mr 45,000, 71 ,000 or 110,000 in the reduced state
and they may be seen as Mr 140,000 or larger polypeptides in their
unreduced state [2, 3, 11, 17, 27, 29, 32-37]. Multimerization is facilitated by
the presence of calcium and reduction to the basic subunit requires
treatment with 5M guanidine [38]. The TcR a and

4
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chains are Mr 35,000
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and 45,000 respectively [21, 39-42]. Also, unlike TABM which may be found
as a soluble or as a merrlbrane bound form, the TcR has only been identified
associated with the cell

membrane.

Amino acid composition,

however,suggests some similarity of TABM to TcR a or (3 [40].
TABM have been isolated from (a) culture media of hybridomas [4] or
T cell clones [18, 34, 43], (b) normal and hyperimmune serum in mice [7, 8,
20, 35], (c) normal human serum [44] and d) ascites fluid [20, 38] of antigen-

specific T cell hybrids. In addition to detecting TABM in normal mouse sera,
Cone et al. [20], also demonstrated TABM in the sera of immunized and
desensitized mice. Although a modest (1-2 fold) increase in total TABM
levels was obtained after immunization only, a 300 fold increase in total
serum TABM was observed within 12 hours of administering a desensitizing
dose of antigen into primed mice. The TABM detected was both specific for
the desensitizing antigen and antigen nonspecific suggesting both an
antigen specific and nonspecific component to desensitization. Ferguson
and Iverson, [7] hyperimmunized mice to SRBC or HRBC and demonstrated
production of the antigen binding portion of the two chain T suppressor
inducer factor (TABM) in the serum using a monoclonal antibody to murine
TABM. This molecule was dependent on an antigen-nonspecific co-factor
for suppressor activity. Finally, DiBrino et al. [44] isolated TABM from normal
human sera using procedures that have been developed to isolate murine
TABM.

The

human

TABM

demonstrated

a

mobility

in

immunoelectrophoresis as do the antigen-specific molecules of mice, and it
represented 0.020/0-0.050/0 of the total serum protein.

Also, the antigen

binding molecules identified were bound by an antiserum made against a
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synthetic peptide corresponding to the J region of the TcR

J3 chain which

suggested a possible homology between the human serum protein and the
TcR

J3 chain.
In general, polyclonal TABM are heterogeneous in charge, whereas

monoclonal TABM exhibit charge homogeneity [33]. Their isoelectric point
range is between 4.9-7.2 depending on the specific TABM.

TABM are

insoluble in water and precipitate with 43-50 percent (NH4)2S04 indicating
that these molecules are globulins.

There is evidence that, like

immunoglobulins, common antigenic determinants exist on TABM [45].
Peptide mapping using Staphylococcus V8 protease and amino acid
analysis have revealed similarities and distinctions between different
antigen specific TABM, which suggests constant and variable regions of the
molecules. Also, several heteroantisera to murine or rat TABM prepared
against different antigens bound to many of the TABM. This represents a
"constant region" for binding by the T cell secreted products.

However,

these proteins are clearly T cell secreted [1, 3-10, 12, 16, 20-22, 25-28, 32,
33, 38-40, 44-52] and therefore differ from B-cell secreted immunoglobulins.

FUNCTIONS OF SOLUBLE TABM

A) Immunoregulation
The activity of soluble TABM depends on their structure and
association with other proteins [3, 6, 18, 23, 43]. These accessory molecules
(NAgBC) do not bind antigen; they bear serologic la or I-J determinants and
determine the genetic restriction required for interaction with target cells [22,
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23, 43].

The TABM

(AgBC) combined with the NAgBC comprise the T

suppressor (TsF) and T helper (ThF) factors.
The action of the T cell suppressor circuit will ultimately result in
suppression of T-helper activity and involves a complex set of T cell
interactions [53]. Suppression begins by activating a suppressor inducer
population of T cells. These inducer cells are CD4+,CD8-, I-J+ [6, 8] and are
responsible for producing the TslF (T suppressor inducer factor) which is
composed of an antigen binding, (AgBC) chain and a non-antigen binding
(NAgBC) chain [23, 46]. This group of cells then "induces" the transducer
cells (TTrans), which are CD4+,CD8-, I-J+.

Communication between the

inducer cells and the transducer cells is restricted by gene products of the
IgVh region of chromosome 12 (in the mouse) [54]. The transducer cells
communicate with a T suppressor effector cell which is CD4+,CD8-, I-J-, and
produces a T suppressor effector factor (TsEF).

This factor contains an

antigen binding chain only, but will induce production of the appropriate
nonantigen-binding, I-J+ chain from a CD4+,CD8-, I-J+ cell. In the murine
model, this interaction between the two chains is restricted by gene products
of the I-E region of the MHC, while the biologic action of this complex is
restricted by the IgVh region of chromosome 12. [8] The final result of the
TsEF is suppression of helper T (TH) cells.
Flood, et al. [6] combined the AgBC from a Ts inducer factor (TsIF)
with an I-J+, NAgBC from F12, a T cell hybridoma that secretes an
Azobenzene arsonate (ABA)-specific TsF, and produced a fully functional T
suppressor factor.

This factor demonstrated an Igh-V-linked genetic

restriction in its activity, apparently controlled by the NAgBC, I-J+ element.
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The genotype of the cell that produced the AgBC was irrelevant; the Igh
haplotype of the cell that produced the NAgBC was the restricting element.
In a similar series of experiments in which hybrid AgBC-NAgBC
complexes were produced, Flood at al. [22] demonstrated that the function of
the regulatory complex is determined by the AgBC and the target cell is
determined by the NAgBC. The authors combined the AgBC of the TslF with
the NAgBC from a TsEF and demonstrated suppression of the T-helper (TH)
dependent function. Similarly, when the AgBC of the TsEF was combined
with the NAgBC from a TsIF, induction of suppression (via action on the
TTrans) was demonstrated and no effect on the TH was observed. These
findings are consistent with their model in that the TslF delivers the message
to the TTrans to induce suppression while the TsEF delivers its message to
the TH cell to suppress T-cell help. Therefore, the NAgBC must interact with
an Igh-linked product on the appropriate target cell while the AgBC binds the
appropriate Ag to deliver the specific signal to the cell.
Many other investigators have substantiated these results by
demonstrating that two disulfide linked molecules are required for
suppressor function:

one antigen specific, I-J- and another antigen

nonspecific, I-J+ [4, 5, 8, 23, 43, 46, 55]. Also, the genetic restriction for the
Igh linked determinants of the TsF is contained in the I-J+ portion while the
antigen specificity is contained in the I-J- portion [6, 22, 23, 46]. Lowy et al.
[43] analyzed a suppressor factor secreted from an ABA specific Ts
hybridoma and a SRBC factor by separating the NAgBC from the AgBC and
recombining them to form hybrid TsF. They demonstrated that an ABA I-J/SRBC I-J+ hybrid factor suppressed an ABA but not a SRBC response
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whereas an ABA I-J+/SRBC I-J- hybrid suppressed only a SRBC response.
Similarly, when an I-J+ chain of 810.A (lgh-1 b) mice was added to an I-Jchain from A/J (lgh-1 e) mice, the resulting complex could suppress the cell
mediated response of the B10.A mice but not of the AlJ mice. Because the
mice possess different Igh-1 allotypes, the authors conclude that the I-J+
portion of the TsF is critical in determining the genetic restriction of the
message.
The immunoregulatory circuit involved in suppression of delayed type
hypersensitivity (DTH) is slightly different [8]. CD4+,CD8- T cells from mice
exposed topically to antigen produce an AgBC and CD4-,CD8+ T cells
exposed to the antigen produce a NAgBC.

Neither chain alone will

suppress the transfer of DTH, although when combined these chains are
able to suppress the transfer of DTH in an antigen-specific manner. When
exposed to specific antigen, the AgBC from the CD4+,CD8- T cell induces
production of a NAgBC by an CD4-,CD8+ , I-J+ T cell.
Little, at al. [56] identified a T-helper factor (THF) which had the ability
to augment contact sensitivity in mice. The factor consisted of two disulfide
bonded chains: one antigen binding and one non-antigen binding.

The

antigen binding chain was responsible for the specificity of the complex and
the non antigen binding chain was responsible for controlling the activity of
the complex in an I-A restricted manner. Thus, reconstitution of the two
chains of the THF requires that the sources be matched at the I-A region of
the MHC. This is similar to the TsF subunits which must be matched at the 1J region.
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B) TABM in Immune Responses
Some TABM have the ability to transfer contact sensitivity in a manner
similar to that of immediate type hypersensitivity [2, 16, 27, 28, 52]. In the
classical hypersensitivity reaction IgE binds to mast cells through their Fc
receptor.

Upon binding to allergen (antigen), the mast cell degranulates

causing release of biologic mediators (including histamine) responsible for
the sequelae observed in contact sensitivity. Askenase, et al. [27] obtained
an antigen specific factor from T cells and injected it into mice to
demonstrate an antigen specific immediate hypersensitivity like reaction.
This response was independent of IgE but was dependent on the presence
of mast cells. The authors propose that TABM, like IgE, bind to the mast cell
and cause release of mediators when exposed to antigen.

The TABM

response is thought to be due to the release of serotonin rather than
histamine because the response is inhibited by treatment with reserpine, a
monoamine-depleting drug that depletes serotonin from mast cell granules
[57]. In general, the response seen with TABM is slightly less intense and
shorter acting than the IgE response.
In an attempt to determine if the TABM and IgE bind to the same
receptor, Kraeuter-Kops, et al. [28] used an in vitro indirect rosette assay to
demonstrate that antigen specific factors (TABM) interact with the mast cell
surface. The authors combined hapten-conjugated sheep red blood cells
(SRBC) and mouse peritoneal mast cells and added antigen specific factors,
IgE or IgG. This resulted in formation of rosettes, and this response was
antigen specific.

Antigen specific rosette formation was detected in the

presence of nanogram quantities of TABM while more than 10 times greater
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amounts of IgE were needed to produce IgE-mediated rosettes. Removal of
the TABM from the system removed the ability to form TABM rosettes and
removal of IgE blocked the ability to form IgE rosettes.

Similarly,

preincubation of mast cells with IgE of various specificities, but not other
immunoglobulin isotypes, blocked IgE rosettes but not TABM-induced
rosettes, and preincubation of mast cells with antigen blocked antigen
specific rosette formation but not IgE rosette formation.

These results

suggest that the TABM interacts with a unique receptor on the surface of the
mast cell in the mouse.
Helfgott, et al. [58] have injected a collagen-specific molecule from a
collagen specific T-cell clone into the synovia into rats and induced arthritis
when exposed to antigen. This arthritogenic factor (AF) was a 65 kD protein
and has also been isolated from rats with adjuvant-induced arthritis [37].
The synovitis was apparent within 48 hours of injection, arguing against the
possibility of B-cell recruitment or antibody production.

Also, addition of

cobra venom factor did not alter the response, suggesting the response is
independent of complement. Thus, it appears that in addition to their potent
role in immunoregulation, some TABM are also involved in the immune
response.

TABM AND THE T CELL RECEPTOR

Several investigators have recently studied the apparent association
between the TcR and TABM [40-42, 51, 59-62]. Moorehead, et al. [51]
observed that an anti-TcR antibody binds to an antigen specific T suppressor
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factor and concluded that the TcR

and TABM at least share serologic

determinants. Similarly, Schluter and Marchalonis [63] prepared a synthetic
peptide that corresponds to the J region of the TcR J3 gene. Antibodies to
this peptide bound to human, dog and murine IgG (particularly to

K

light

chain) and also bound to a murine suppressor cell. Hubbard et al. [40] have
also shown that TABM bear the

J~

determinant, thus supporting the

contention that TABM and the TeR share serologic determinants. Guy et al.
[25] hypothesized that the antigen specific helper factor actually represents a
soluble form of the TcR. Their helper factor was a disulfide-linked dimer that
was precipitated from cell-free supernatants of cloned TH cells with a
monoclonal antibody specific for the TcR

V~8

determinant.

Many problems arise when thinking of TABM as a soluble form of the
TcR. Firstly, TABM do not need MHC to recognize antigen, and the TcR must
"see" antigen and MHC together in order to respond. Although there have
been reports of the TcR binding nominal antigen [64] the binding was with
extremely low affinity. Also, the genes that code for the

f3 chain

of the TcR are

not always present in the T cell hybridomas that produce TABM [65]. It is a
possibility that the

~

chain is responsible for the MHC restriction and the

accessory molecule, and the ex chain is involved in the TABM and antigen
recognition.
The relationship between TABM and the TcR was also examined
through the use of antisense oligodeoxynucleotides [19, 66].

Using an

antigen-specific factor derived from a TH hybridoma, A1.1, the authors showed
that antisense corresponding to the Va oligodeoxynucleotides inhibited CD3
expression on trypsin treated cells and also inhibited production of the antigen
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specific factor. Factor production was restored after removal of antisense Va.
Cells treated with antisense to TcR a without prior trypsin treatment expressed
normal levels of cell-surface CD3 and TcRaf3 but were unable to produce the
factor. Also, cells treated with antisense corresponding to Vf3 did not produce
CD3 but did produce the factor.

This indicates that cell surface TcRn is

involved in production of the factor, but it probably is not the source of the
factor [66]. More recently, Green et al. [19] used retroviral vectors to transfer
the TcRn and/or f3 cDNA from A1.1 to other cell lines and demonstrated that
cells expressing A1.1 TcRn, with or without A1.1 TcRf3, produced the antigen
specific factor. The authors concluded that the TcR a chain gene from A1.1
confers the ability to produce the factor on other T cell lines, including lines
incapable of expressing cell-surface TcR.
In a similar experiment to that of Flood et al. [22], Fairchild et al. [61]
separated the NAgBC from the AgBC and observed that the AgBC expressed
an epitope bound by a mAb specific for a TcR a-chain-constant region
determinant. Also, the NAgBC expressed an epitope bound by an

anti-V~8

mAb. By forming hybrid complexes using chains of either Kd or Dd restriction,
the authors observed that the NAgBC was responsible for the MHC restriction
while the AgBC was responsible for the antigen specificity for the functioning
complex. Their results suggest that the TcR a chain may be related to the
TABM and the TcR f3 chain may be related to the accessory molecule.
The difference still remains however in molecular size between the Va
and TABM. As stated earlier, TABM is composed of multimers of a 22.5 kD
soluble molecule while the a chain has only been identified as a 35 kD
membrane bound molecule. In addition, preliminary sequencing using a Ts
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cDNA library and a panel of monoclonal antibodies as probes, Kraig has
determined that the cDNA for the antigen receptors on the Ts cells does not
correspond to any known Ig or TcR gene [67]. Future investigations may find
that the membrane bound TcR may be cleaved and/or altered in such a way
that it would resemble soluble TABM. The fact remains, however, that in its
membrane bound state the TcR and TABM represent different entities and
they must be treated as such.

MATERIALS AND METHODS

ANIMALS

BALB/c mice approximately 6-8 weeks old were obtained from Charles
River Breeders (Wilmington, MA) or Harlan Laboratories (Indianapolis, IN).
C.B. 17-scid mice were obtained from the breeding colony of Dr. Leonard
Schultz, Jackson Laboratory. Because of their immunodeficiency, the scid
mice were maintained on a combination of sulfamethoxazole and
trimethoprim.

All animals were

maintained by the Center for Laboratory

Animals at the University of Connecticut.

ANTI-TABM

Rabbit anti-mouse TABM that has been previously prepared in our
laboratory was used [33]. In brief, rabbits were immunized by subcutaneous
injection of 25Jlg of Mr 110,000 TABM specific for Azobenzene arsonate
(TABM-ABA) in complete Freund's adjuvant.

Two weeks later they were

injected with another 25 Jlg TABM-ABA in Freund's incomplete adjuvant. Two
weeks following this they were challenged by intravenous injection of 50Jl9
TABM-ABA in 300 ).1g polyadenylic:polyuridylic acid (Poly A:U,BoehringerIngelheim, Danbury, CT). Rabbits were bled at least 7-10 days after the final
boost. The antiserum was adsorbed with sepharose beads conjugated with
murine Ig or albumin and was screened in ELISA for binding specificity to
TABM. The antiserum binds the constant region of secreted TABM [45] but
does not bind immunoglobulin or murine serum albumin.
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IMMUNIZATION

BALB/c mice were immunized by intraperitoneal injection of 500 Jlg
ovalbumin (OVA), hen egg lysozyme (LYS), or bovine serum albumin (BSA)
(all obtained from Sigma) as antigens combined with polyadenylic polyuridylic
acid (Poly A:U) adjuvant. Some of the mice were boosted 2 weeks later with
another 500 Jlg of antigen in sterile PBS.

The mice were bled from the

retroorbital venous plexus at various days up to 21 days post-immunization.
The serum was aliquoted and maintained at 40 or -20 0 C until it was used.
Some mice were immunized with different amounts of antigen ranging from 5
Jlg to 15 mg combined with 300fl9 poly (A:U). The mice were then bled as

before on day 14 and the responses for TABM and immunoglobulin
production were compared. Scid mice were immunized as described above
or received a suspension of 5 x 10 7 BALB/c thymocytes in sterile PBS
administered iv, and two weeks later were injected Lp. with 500 Jlg BSA
combined with 300 Jlg poly (A:U). Two weeks later the mice were challenged
with 500 Jlg BSA in sterile PBS. The serum was collected 14 days after the
challenge and TABM and immunoglobulin production were monitored by
ELISA.

THYMOCYTE PREPARATION

Thymocytes for reconstitution of the scid mice were obtained from
nonimmunized 6 week old BALB/c mice. The mice were euthanized using an
ether chamber in a hood and the thymi were removed and placed in sterile
PBS. A cell suspension was obtained by gently extruding the thymocytes from
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the capsule with injection of sterile PBS into the thymus. The thymocytes were
assessed for viability using trypan blue exclusion.

Fifty million thymocytes

were suspended in 0.5 ml sterile PBS and administered iv to the scid mice.

ELISA
Assays were performed using ELISA trays coated with 1 Jlg/well of
specific antigen.

Coating was done in coating buffer consisting of 0.1 M

NaHC03 made pH 9.25 with Na2C03.

The trays remained at room

temperature overnight. The trays were blocked with 200 JlI 0.1 % BSA or OVA
per well and incubated for 1 hour at 37° C. The trays were washed five times
between all steps with wash buffer (10nM K2HP04, 0.1 % Triton X 100 and
0.85%

NaCI made pH 7.4 with KH2P04).

Dilutions of immunized mouse

serum (ranging from 1:100 to 1:14) were added at 100 JlI/well and again the
trays were incubated for 1 1/2 hours at 37° C. After washing, 100 Ill/well of
rabbit anti-mouse TABM (R33), rabbit anti-mouse immunoglobulin or normal
rabbit serum (NRS) at a dilution of 1:500 was added and incubated as above.
Anti-BSA was added to wells without serum as a positive control. Then, 100
JlI/well of 1:1 000 alkaline phosphatase conjugated goat anti-rabbit

IgG

(TAGO, Burlingame, CA) was added and incubated for 1 1/2 hours at 370 C.
Finally, 100 JlI of 1 mg/ml p-nitrophenylphosphate in substrate buffer (105
mg/ml diethanolamine and 10 Jlg/ml MgCI2 made pH 9.8) was added to each
well. The trays were incubated until an OD of 1.5 was obtained for the positive
control. Absorbance was monitored at 41 0 nM.
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PURIFICATION OF TABM BY AFFINITY FOR ANTIGEN

BALB/c mice were immunized with BSAlpoly (A:U) and challenged with
BSA as described above. Fourteen days after challenge, the mice were bled
and the sera was pooled. One ml of sera (diluted 1:2) was mixed with 1 ml
sepharose beads conjugated with BSA or OVA at 5 mg protein/ml beads. The
beads were washed 3 times with PBS and eluted with 1 ml 2x SDS sample
buffer. One ml of the eluate was reduced with 60/0

~-mercaptoethanol

and

alkylated with 7%(vol/vol) lodoacetamide. Four JlI of this eluate was resolved
by SDS-polyacrylamide electrophoresis (PhastGel, Phastsystem; Pharmacia)
and a Western Blot analysis was performed to identify the antigen specific
TABM and immunoglobulins.

IMMUNOBLOT ANALYSIS

The sample was resolved by SDS-polyacrylamide electrophoresis as
described above and the gel was transferred to nitrocellulose paper
(Immobilon-P) using wet electrophoretic elution. After the filter was rinsed
several times with PBS, it was blocked with 0.5°/0 Tween (polyoxyethylenesorbitanmonolaurate) and incubated at room temperature for 1 hour. Next,
rabbit anti-mouse TABM was added at a dilution of 1:400 and this was
incubated overnight at 40C. Following another wash, alkaline phosphataseconjugated goat anti-rabbit IgG (1:1 000) was added and again the paper was
incubated for 2 hours at 40 C.

Finally, substrate (300/0H202, 3 mg/ml

chloronaphthol in 100°10 methanol, and tris buffered saline) was added and
color change was monitored. The reaction was stopped with cold water after
5 minutes.
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DATA ANALYSIS

For each experiment the average and standard deviation were
determined from 3 data points.

Statistical significance was determined

using the students t-test or 2 way Analysis of Variance (ANOVA).

RESULTS

DETECTION OF TABM IN THE HUMORAL IMMUNE RESPONSE

To measure a humoral immune response, mice were immunized with
500Jlg BSA /300Jlg poly (A:U) and challenged after two weeks with another

dose of antigen in sterile PBS. Sera were obtained prior to immunization
and on days 3,7,10,14,18, and 21 after primary immunization or secondary
challenge and were tested in ELISA for BSA-specific TABM or
immunoglobulin. The kinetics of the serum TABM and immunoglobulin for
the primary and secondary response was examined. The average of three
data points was used to obtain a value and standard error for each day at
each dilution.

The average value obtained for the preimmunized control

sera was subtracted from each experimental average to determine the net
value for each day (see Table 1).
Figure 1A is representative of the primary response for TABM
production. TABM specific for BSA were detected by day 7 and peak levels
did not appear until day 18 after which time the levels decreased (Figure
1A). Figure 1B shows that anti-BSA-immunoglobulin was detected 7 days
after immunization, increased slightly by day 10, and remained stable 21
days after immunization.

In comparison, Figures 2A and B show the

secondary responses for BSA-specific TABM and immunoglobulin
respectively.
This data is summarized in Figures 3 A and B. The titer for each day
was determined as the minimum amount of serum (or dilution) required to
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achieve an 00 reading of 0.2. These figures represent the results of three
groups of animals and three experiments performed on each group.

In

general, the TABM response after the challenge was stronger, peaked
concurrent with immunoglobulin, and began to decline while the
immunoglobulin titer remained stable. This demonstrates that the TABM
kinetics differed temporally from antigen-induced immunoglobulin
production.

STORAGE OF SERA FOR TABM
In order to determine optimal storage conditions for TABM the
collected sera were maintained at 40C or -200C.

Because TABM are

globulins and tend to stick to glassware and plastic containers, especially
when they are repeatedly frozen and thawed [33, 49], the serum was
aliquoted prior to freezing. Figure 4 shows the results of an ELISA using
serum that had been in the refrigerator for 10 days prior to testing compared
to sera that was frozen immediately after obtaining it. TABM were identified
with R33. The sera stored in the refrigerator lost all activity while the sera
stored in the freezer maintained high TABM levels.
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DOSE RESPONSE OF TABM AND IMMUNOGLOBULIN
PRODUCTION

In order to study the dose response of TABM and immunoglobulin
production, various amounts of antigen were administered to the mice and
the sera were collected on day 14. Figure 5A is representative of the dose
response for TABM production. TABM were produced with an antigen dose
of 50Jlg BSA and the response slowly rose with increasing amounts of
antigen, peaked at 10 mg, and decreased by 15 mg.

Figure 5B is

representative of the dose response for imunoglobulin production. In this
experiment, immunoglobulin were produced by 50 Jlg and the titer did not
decrease until 10-15 mg.
This data is summarized in Figure 5e. The titer for each antigen dose
was determined as the minimum amount of serum (or dilution) required to
achieve an OD reading of 0.2. This figure represents the results of two
groups of animals and three experiments performed on each group.

In

general, the immunoglobulin titer peaked at a much smaller dose than
TABM and decreased as the TABM titer increased. By 15 mg both TABM
and immunoglobulin titers had decreased. This data again demonstrate that
the TABM response is different that that of immunoglobulin.

ANTIGEN SPECIFICITY OF TABM PRODUCTION

In order to demonstrate antigen specificity of the TABM, mice were
immunized with either BSA or LYS and the sera were collected on day 14
after immunization. The sera were then tested in ELISA for binding to either
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BSA or LYS. Figure 6A shows the results of 8SA-immunized sera tested
against BSA or LYS coated plates and figure 68 shows the results of LYS immunized sera tested against BSA or LYS coated plates.

The BSA-

immunized sera only bound to the BSA while the LYS sera only bound to
the LYS coated plates.
Antigen specificity was further investigated by performing an
immunoblot analysis on serum proteins purified by affinity for antigen. The
sera from BSA immunized mice were collected 14 days after antigenic
challenge and adsorbed to either BSA or OVA-sepharose beads. The sera
were eluted with SDS polyacrylamide gel sample buffer to remove adsorbed
proteins.

The eluted proteins were detected by SDS-PAGE and

immunoblotting with anti-TABM or anti-immunoglobulin. As shown in figure
7A, BSA specific TABM of Mr 110,000 were detected in the eluate from the
BSA-sepharose beads while no TABM were detected in the eluate from the
OVA-sepharose. TABM were also detected in the effluent from BSA and
OVA-sepharose beads. BSA-specific immunoglobulins were also detected
in the eluate of the BSA-sepharose (Figure 7B). Proteins eluted from the
BSA-sepharose were resolved after reduction at Mr 84,000, 47,000 and
25,000 which are consistent with immunoglobulin ).1,1', and light chains.
Immunoglobulin was also detected in the effluent from both the BSA and
OVA-sepharose beads but no immunoglobulin was detected in the eluate of
the OVA-sepharose.

These results demonstrate that TABM (and

immunoglobulin) produced upon stimulation with BSA bind only to BSA and
do not bind to LYS or OVA.
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DETERMINATION THAT TABM ARE T CELL DERIVED

To further document the cell origin of the TABM produced,
immunodeficient scid mice were reconstituted with thymoctes (to reduce the
possibility of contamination with B lymphocytes). Prior to treatment the mice
were anesthetized and bled through the retroorbital venous plexus. The
sera were tested in ELISA with anti-Ig to confirm that the scid mice were not
producing endogenous immunoglobulin. Any scid determined to be "leaky"
based on this assay was not used in any further experiments. The mice
were primed with BSA/poly(A:U) and challenged with BSA and the sera
were collected on day 14 after challenge.

Figure 8A shows that

unreconstituted scid mice failed to produce BSA-specific TABM compared
to the BALB/c control (p<O.01) (Figure 8B). However, after reconstitution
with thymocytes, the scid mice produced an amount of BSA-specific TABM
consistent with that of the BALB/c control (p>O.01). The reconstituted mice
did not, however, produce immunoglobulin specific for BSA (p<O.01) (Figure
Be).
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Table 1
Sample Calculation for TAB M Production
Sera was collected on day 0 (pre-immunized) and on various days postimmunization. For each day the average value was determined from 3 data
points in ELISA. The average for the preimmunized control was subtracted
from each experimental average to determine the net average for each day.
Normal rabbit serum control is also shown.

NBS

833
ULSEBUM

DAyQ

pAY 14

DAY 14 NET

DAY 14

1.0

.138

.265

.127

.104

4.0

.359

.828

.469

.132

7.0

.516

1.112

.596

.121
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Figure 1A: TABM Production in the Primary Response

BALB/c mice were

immunized with BSAlpoly (A:U). Sera were collected prior to immunization
and on days 3, 7, 10, 14, 18, and 21 post-immunization and tested for BSAspecific TABM in ELISA. This graph is representative of the data used to
determine titers for TABM production in the primary response. Each point
represents the net average of three data points after the control average was
subtracted.
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Figure 1B: Immunoglobulin Production in the Primary Response BALB/c
mice were immunized with BSA. Sera were collected prior to immunization
and on days 3, 7, 10, 14, 18, and 21 days post-immunization and tested for
BSA-specific immunoglobulin in ELISA. This graph is representative of the
data used to determine titers for immunoglobulin production in the primary
response. Each point represents the net average of three data points after
the control average was subtracted.
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Figure 2A: TABM Production in the Secondary Response

BALB/c mice

were immunized with BSA/poly (A:U) and challenged with BSA. Sera were
collected prior to immunization and on days 3, 7, 10, 14, 18 and 22 days
post-challenge and tested for BSA-specific TABM in ELISA. This graph is
representative of the data used to determine titers for TABM production in
the secondary response.

Each point represents the net average of three

data points after the control average was subtracted.
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Figure 28:

Immunoglobulin Production in the Secondary Response

BALB/c mice were immunized and challenged with BSA/poly (A:U). Sera
were collected prior to immunization and on days 3, 7, 10, 14, 18 and 21
days post-immunization and tested for BSA-specific immunoglobulin in
ELISA. This graph is representative of the data used to determine titers for
immunoglobulin production in the secondary response.

Each point

represents the net average of three data points after the control average was
subtracted.
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Figure 3A: Primary Response: TAB M and Immunoglobulin

BALB/c mice

were immunized with BSA/poly (A:U). Sera were obtained at the indicated
times and tested in ELISA for binding to BSA. Titers were determined as the
amount of serum/100JlI for TABM or dilution of serum for immunoglobulin
required to achieve an 00 of 0.2 after the control was subtracted. The data
represent the averages of three groups of animals and three ELISA
expe ri ments/g roup.
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Figure 3B: Secondary Response: TABM and Immunoglobulin BALB/c mice
were immunized with BSA/poly (A:U) and challenged with BSA. Sera were
obtained at the indicated times and tested in ELISA for binding to BSA. The
titers were defined as the amount of serum/1 00J.11 for TABM or the dilution of
serum for immunoglobulin required to achieve an OD of 0.2 after the control
was subtracted. The data represents the average of three groups of animals
and three ELISA experiments/group.
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Figure 4: Storage of Sera for TABM BALB/c mice were immunized with
BSA/poly (A:U) and the sera were collected 14 days later and stored in the
refrigerator or the freezer for 10 days.

The BSA-specific TABM were

identified using R33. Each point represents the net average of three data
points after the control average was subtracted.
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Figure SA:

Dose Response of TABM Production

BALB/c mice were

immunized with 50, 500, 5000, 10000 or 15000 fJ,g of BSA combined with
300 Jig poly (A:U). Sera were obtained on day 14 after immunization and
tested in ELISA for TABM binding to BSA. This graph is representative of
the data used to determine titers for TABM production.

Each point

represents the net average of three data points after the control average was
subtracted.
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Figure 58: Dose Response of Immunoglobulin Production

BALB/c mice

were immunized with 50, 500, 5000, 10000 or 15000 Jlg of BSA combined
with 300 Jlg poly (A:U). Sera were obtained on day 14 after immunization
and tested in ELISA for immunoglobulin binding to BSA.

This graph is

representative of the data used to determine titers for TABM production.
Each point represents the net average of three data points after the control
average was subtracted.
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Figure 5C:

Dose Response of TABM and Immunoglobulin Production

BALB/c mice were immunized with 5, 50, 500, 5000, 10000 or 15000 Jlg of
BSA combined with 300Jlg poly (A:U). Sera were obtained on day 14 after
immunization and tested in ELISA for binding to BSA. TABM specific for
BSA was identified using R33 and immunoglobulin specific for BSA was
identified with rabbit anti-lgG (heavy and light chains).

The titers were

defined as the amount of serum/1 OOJlI for TABM or the dilution of serum for
immunoglobulin required to achieve an OD of 0.2 after the control was
subtracted. The data represents the average of two groups of animals and
three ELISA experiments/group.
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Figure SA: Antigen Specificity of TABM: Immunized with BSA BALB/c mice
were immunized with 500Jl9 BSA/poly (A:U) and the sera were obtained on
day 14 after immunization. Sera were tested for binding to BSA or LYS
coated plates in ELISA. Each point represents the net average of three data
points after the preimmunized control average was subtracted.
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Figure 6B: Antigen Specificity of TABM: Immunized with LYS BALB/c mice
were immunized with 500Jlg LYS/poly (A:U) and the sera were obtained on
day 14 after immunization.

Sera were tested for binding to BSA or LYS

coated plates in ELISA. Each point represents the net average of three data
points after the preimmunized control average was subtracted.
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Figure 7 A: Immunoblot· of TABM Specific for BSA

BALB/c mice were

immunized with BSA/poly (A:U) and were challenged with BSA 14 days
later. The mice were bled 14 days after the challenge and the serum was
collected.

The serum was mixed with BSA-sepharose or OVA-sepharose

beads and bound proteins were eluted with SOS sample buffer. The eluted
proteins were reduced, alkylated, resolved in 10-150/0 polyacrylamide gels
and transferred to immobilon. The blotted proteins were detected with antiTABM (R33). Lane A: Proteins eluted from BSA-sepharose; Lane B: Effluent
from BSA-sepharose; Lane C: molecular weight standards; Lane 0: Proteins
eluted from OVA-sepharose; Lane E: Effluent from OVA-sepharose.
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Figure 7B: Immunoblot of Immunoglobulin Specific for BSA BALB/c mice
were immunized with BSA/poly(A:U) and were challenged with BSA 14 days
later. The mice were bled 14 days after the challenge and the serum was
collected.

The serum was mixed with

BSA-sepharos~

or OVA-sepharose

beads and bound proteins were eluted with SDS sample buffer. The eluted
proteins were reduced, alkylated, resolved in 10-15%

polyacrylamide gels

and transferred to immobilon. The blotted proteins were detected with antiimmunoglobulin.

Lane A: Proteins eluted from BSA-sepharose; Lane B:

Effluent from BSA-sepharose; Lane C: molecular weight standards; Lane 0:
Proteins eluted from OVA-sepharose; Lane E: Effluent from OVA-sepharose.
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Figure 8A: Production of TABM in Unreconstituted scid Mice Scid mice
were immunized with BSA/poly (A:U) and challenged with BSA 2 weeks
later.

Sera were collected on day 14 after the challenge.

BSA-specific

TABM (using R33) were identified in ELISA and are expressed as the 00
given by 7JlI serum/1 OOJlI buffer. The results are the mean ± SE of 6 mice.
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Figure 88: Production of TABM in Reconstituted scid Mice Scid mice were
reconstituted with 5x10 7 BALB/c thymocytes, and were immunized with
BSA/poly (A:U) 2 weeks later. They were challenged with BSA 2 weeks
after the primary immunization and sera were collected on day 14 after the
challenge. BSA-specific TABM (using R33) were identified in ELISA and are
expressed as the 00 given by 7J.l1 serum/1 OO~I buffer. The results are the
mean ± SE of 6 mice.
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Figure Be: Production of Immunoglobulin in Reconstituted scid Mice Scid
mice were reconstituted with 5x10 7 BALB/c thymocytes, and were
immunized with BSA/poly (A:U) 2 weeks later. They were challenged with
BSA 2 weeks after the primary immunization and sera were collected on day
14 after the challenge. BSA-specific immunoglobulin (using anti-Ig) were
identified in ELISA and are expressed as the 00 given with a dilution of
1:4000. The results are the mean ± SE of 6 mice.

DISCUSSION

TABM have been identified in T cell culture media [5, 18, 34] or
ascites fluid [20, 38] for many years. They also have been reported in both
normal and hyperimmune serum [7, 8, 20, 35, 44].

TABM represent a

soluble antigen-specific effector mechanism of regulatory T lymphocytes and
participate in immunoregulatory activities [2, 7, 14, 15, 34, 52].

We

reasoned, therefore, that they may be induced to appear as soluble products
in an immune response similar to B cell produced antigen specific
immunoglobulins. We have used an ELISA-based antigen binding assay to
detect antigen-specific TABM because of the extreme sensitivity of the assay
and its dependence on primary binding. This assay will detect as little as
100 ng TABM, and TABM will bind (nominal) antigen in the solid or liquid
phase [34, 38, 45, 48].
An immune response is characterized by: 1) inducibility; 2) specificity
and 3) memory. We have demonstrated that TABM production fulfill all of
these criteria. The TABM response is inducible because TABM that bind the
immunizing antigen

~

rise during the immune response. Also, a second

challenge with antigen resulted in a stronger response
antigen.

~

to the primary

Thus, the TABM response was inducible, specific and

demonstrated memory.
We have used a heteroantisera to TABM (R33) that was previously
prepared in our laboratory. This antisera does not bind immunoglobulins or
murine albumin [49] indicating that TABM are not B cell-derived
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immunoglobulins or a common serum protein. In addition, our data clearly
show that the TABM response is temporally distinct from that of
immunoglobulin after antigenic stimulation. The trend in six experiments
was that TABM levels in the primary response peaked two days later and
declined sooner than immunoglobulins. The secondary response showed
that TABM production occurred concurrently with immunoglobulin
production, but the TABM titer decreased while the immunoglobulin titer
remained stable.

This evanescent TABM response appears to be

characteristic and provided further evidence that TABM are not B cellderived immunoglobulins.
TABM production also differed from immunoglobulin production at
different antigen doses. TABM production peaked at 10 mg BSA and then
decreased, while immunoglobulin production peaked by 50 )lg, plateaued
through 5 mg, but then decreased. Perhaps the rise in TABM correlates with
an inhibition of immunoglobulin production at extremely high antigen doses.
Immunoblots of TABM bound and eluted from antigen further
substantiated that TABM are not B cell derived immunoglobulins.

In the

reduced form, R33 identified TABM which were resolved as Mr 11 0,000
polypeptides.

Anti-immunoglobulin, however, identified polypeptides that

resolved at Mr 84,000, 47,000 and 25,000 which are consistent with
immunoglobulin )l,y, and light chains.

Previous studies have shown that

TABM (non-radioiodinated) detected in normal sera or purified from ascites
fluid resolve as Mr 110,000 polypeptides which dissociate to the basic
subunit of Mr 22,500 upon treatment with 5M guanidine [32, 33, 49]. Many
investigators have also identified TABM after reduction as Mr 70,000 or
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45,000 polypeptides [3, 7, 33, 44] which most likely represent mulitimers of
the basic subunit.

Scid mice lack the ability to rearrange the V region in both the Igh
and TCRI3 genes, and thus fail to develop mature T or B lymphocytes [68, 69,
70].

Using this model we demonstrated the production of TABM, but not

immunoglobulin, in thymocyte reconstituted, antigen stimulated, scid mice.
This further demonstrated that TABM are indeed distinct from B cellproduced immunoglobulins.

This model also demonstrated that B

lymphocytes are not required for TABM production. In addition, TABM must
require genetic mechanisms similar to the T cell receptor or immunoglobulin
assembly to generate TABM because scid mice did not produce TABM prior
to reconstitution.
TABM levels in normal serum are generally in the fJ,g/ml range,
although BALB/c mice have threefold higher amounts of endogenous TABM
than CBAlJ mice, which suggests that genetic background is an important
factor in TABM levels [20]. Cone et al. [20] demonstrated a modest (1.5-2
fold) increase in TABM levels after immunization only, but observed a
dramatic 300 fold increase in total serum TABM within 12 hr of a
desensitizing dose of antigen given to primed mice. The authors noted an
extremely short serum half-life and concluded that this was understandable
based on the potent immunoregulatory properties of TABM. Our findings
with respect to storage of TABM further substantiate this claim. When stored
in the refrigerator for 10 days, the TABM were unable to bind to specific
antigen. The sera that was aliquoted and placed in the freezer, however,
maintained high binding ability. It is possible that an inactivator is present in
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the sera which is unable to perform at extremely low temperatures. TABM
are also extremely sticky proteins which tend to adhere to plastic or glass
[49].

For this reason our sera was aliquoted and not refrozen after use.

Possibly the TABM in the sera maintained in the refrigerator were also
adhering to the plastic container and thus were unable to bind in ELISA.
The function of soluble TABM depends on their association with other
non-antigen specific proteins. The TABM/accessory molecule complex has
been found to be important in immunoregulation as helper factors [47, 56] or
more commonly as suppressor factors [7, 11, 18, 22, 34]. They also have
been demonstrated to transfer contact sensitivity in a manner similar to that
of immediate type hypersensitivity [2,16,27,28,52]. In addition, TABM have
been shown to regulate the IgE response through control of post
translational glycosylation of IgE binding factors [71]. While the idiotypic
determinants of TABM correlate with the antigen specificity of the TsF, the
isotypic determinants correlate with their biologic activity. Different TABM
subtypes have been identified based on their ability to react with distinct
subsets of anti-TABM antisera (R.E.Cone, unpublished observation).
Although we have not employed functional assays, our data suggests
that the TABM generated in this humoral immune response are the
immunoregulatory type. The dose response data clearly shows that at high
antigen doses (10 mg) TABM are produced at relatively high levels while
immunoglobulin production is decreased dramatically. It is possible that the
TABM are suppressing immunoglobulin production at these high antigen
doses or they may be inducing suppression mediated by another TABM
isotype. Additionally, the short half life for TABM activity when the serum is
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maintained in the refrigerator suggests that an inactivator is present in the
serum. This inactivator would be critical if the TABM were to have these
potent immunoregulatory effects.
Antigen-specific immunoregulatory molecules have been shown to
bear epitopes recognized by antibodies specific for T cell receptor alpha
chain constant region [25, 41, 42, 61] although these molecules are not
"conventional" T cell (membrane) receptor alpha chains. Also, TABM used
to prepare anti-TABM antisera bear an epitope present in TcR

VJ~

[40].

Finally, TABM and immunoglobulin have been shown to cross react with
antibodies produced against a synthetic peptide that corresponds to the J
region of the TcR

~

gene. This data suggests that TABM, immunoglobulin

and the TcR share serologic determinants. Our data with the scid mice
suggest that TABM, like immunoglobulin and the TcR, require a rearranging
V region gene. It is possible that TABM utilize the TcR a chain V region
along with a new or modified constant region gene to form the molecule.
Indeed, Zheng et al. [66] demonstrated that a TcR Va gene is required to
produce a functional antigen-specific immunoregulatory molecule. It may be
possible, however, that TABM V genes may represent a third set of
rearranging genes coding for antigen-specific molecules.

CONCLUSIONS

We have demonstrated a new humoral immune response by T
lymphocytes. Upon stimulation with antigen, T cells are induced to produce
soluble products which bind antigen (TABM). This response is specific for
the inducing antigen and is stronger after challenge with antigen.

The

serum TABM do not maintain activity if stored at 40 for extended periods of
time, but must be aliquoted and maintained at -20 0 for consistent results.
The kinetics of TABM production differ temporally from immunoglobulin
production and TABM production peaks at a higher dose of antigen than
immunoglobulin.

TABM were isolated by affinity chromatography and

resolved at Mr 110,000, which is also unlike immunoglobulin. Finally, scid
mice which have been reconstituted with thymocytes are able to produce
TABM but not immunoglobulin, while unreconstituted scid mice do not
produce TABM.

These results indicate a new antigen specific humoral

immune response by the T lymphocyte which may indicate a soluble
extension of T cell function and potent immunoregulatory functions at the site
of antigenic challenge in vivo.
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